Comparison

Nilotinib European Partner

Item no. TMO-T1524-500mg
Manufacturer TargetMol
CASRN 641571-10-0
Amount 500 mg
Quantity options 100 mg 1 mL x 10 mM (in DMSO) 1 mL 200 mg 25 mg 500 mg 50 mg 5 mg
Category
Type Molecules
Specific against other
Citations 1. Maekawa T, et al. Int J Clin Oncol. 2007 Oct;12(5):327-40.
Smiles C(F)(F)(F)C=1C=C(C=C(NC(=O)C2=CC(NC=3N=C(C=CN3)C=4C=CC=NC4)=C(C)C=C2)C1)N5C=NC(C)=C5
ECLASS 10.1 32169090
ECLASS 11.0 32169090
UNSPSC 12000000
Alias Tasigna,AMN107
Shipping Condition Cool pack
Available
Manufacturer - Targets
Autophagy|||Bcr-Abl
Shipping Temperature
Cool pack
Storage Conditions
-20
Molecular Weight
529.52
Description
Nilotinib (AMN107) is a Bcr-Abl tyrosine kinase inhibitor with oral activity. Nilotinib has antitumor activity and may be used for the treatment of Imatinib-resistant chronic myelogenous leukemia (CML).
Pathways
Cytoskeletal Signaling|||Tyrosine Kinase/Adaptors|||Angiogenesis|||Autophagy
Bioactivity
Nilotinib, also known as AMN107, is a tyrosine kinase inhibitor under investigation as a possible treatment for chronic myelogenous leukemia (CML). In June 2006, a Phase I clinical trial found nilotinib has a relatively favorable safety profile and shows activity in cases of CML resistant to treatment with imatinib (Gleevec?), another tyrosine kinase inhibitor currently used as a first-line treatment.
Receptor
Bcr-Abl

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Amount: 500 mg
Available: In stock
available

Compare

Add to wishlist

Get an offer

Request delivery time

Ask a technical question

Submit a bulk request

Questions about this Product?
 
Close